Smith & Nephew Plc Smith & Nephew and Imperial College Partnership
05 September 2017 - 5:00PM
RNS Non-Regulatory
TIDMSN.
Smith & Nephew Plc
05 September 2017
Smith & Nephew and Imperial College partner to develop
enhanced surgical techniques in Sports Medicine
5 September 2017
Smith & Nephew (LSE:SN, NYSE:SNN), the global medical
technology business, is pleased to announce it is partnering with
Imperial College London to develop enhanced surgical techniques
relating to ligament function, biomechanics and soft tissue
injuries of the knee, including the most common injuries of torn
menisci and anterior cruciate ligament rupture.
The three-year partnership with the Department of Mechanical
Engineering at Imperial College London will focus on biomechanical
research into extra-articular ligaments and their functions whilst
gaining valuable insight into the meniscus, the cartilage disk
acting as a cushion between femur and tibia. The meniscus has
limited healing capabilities, with some injuries increasing the
chances of arthritis amongst other debilitating conditions.
"The partnership with Smith & Nephew is priceless for our
work. It allows a strategic attack on the unanswered biomechanical
issues in knee surgery. Knowing funding is secure for three years
allows a step by step 'due diligence' approach to investigating
these issues rather than sporadic studies. This is the best way to
translate from the lab to patient care" said Mr Andy Williams, Lead
Surgical Researcher, Imperial College London and Fortius
Clinic.
It is anticipated that the partnership will increase
understanding of the role of biomechanics in improving knee
stability.
Andy Weymann, Chief Medical Officer, Smith & Nephew,
commented: "Meniscus repair is one of the greatest challenges of
Sports Medicine. By combining the clinical expertise of Imperial
College with our pioneering approach to new product development we
expect to be able both to advance surgical techniques and
accelerate the development of next generation products."
The partnership is being funded by a $1 million grant from Smith
& Nephew.
Professor Andrew Amis, Professor of Orthopaedic Biomechanics and
leader of The Biomechanics Group, Imperial College London, said:
"This programme grant will allow us to follow through on our ideas
from basic anatomy through to design and testing of novel operative
procedures to treat sports injuries of the knee. To be working
alongside Smith & Nephew at the forefront of Sports Medicine is
an exciting prospect."
This partnership follows a recent announcement that Smith &
Nephew have entered a long-term collaboration with The University
of Hull driving research into pioneering approaches to advanced
wound care and in doing so creating one of the largest wound care
R&D clusters in the world.
- ends -
Enquiries
Media
Charles Reynolds
Smith & Nephew +44 (0)1923 477314
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has more than 15,000 employees and
a presence in more than 100 countries. Annual sales in 2016 were
almost $4.7 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZZLFBDKFBBBE
(END) Dow Jones Newswires
September 05, 2017 03:00 ET (07:00 GMT)
Citi Fun 24 (LSE:AP82)
Historical Stock Chart
From Sep 2024 to Oct 2024
Citi Fun 24 (LSE:AP82)
Historical Stock Chart
From Oct 2023 to Oct 2024